Nectar Lifesciences Limited (NSE: NECLIFE) has announced a significant organizational change following the completion of a business transfer agreement dated July 7, 2025. The company has transferred four key management personnel to Ceph Lifesciences Private Limited, effective November 10, 2025, as part of a slump sale involving the transfer of its business related to the manufacture, distribution, marketing, and sale of active pharmaceutical ingredients and formulations.

Management Transfers

The following key personnel have been transferred to Ceph Lifesciences Private Limited:

Implications and Continuity

The transfer of these key management personnel marks a significant shift in Nectar Lifesciences' operational structure. However, the company has taken steps to ensure continuity in its governance:

• Dr. Surulichamy Senthilkumar will continue to serve as a Non-Executive Director of Nectar Lifesciences Limited.
• This new role will be without any remuneration or sitting fee, highlighting Dr. Senthilkumar's continued involvement in the company's strategic direction.

Business Transfer Agreement

The management changes are a direct result of the business transfer agreement between Nectar Lifesciences and Ceph Lifesciences Private Limited. This agreement, which culminated in a slump sale, involves the transfer of Nectar Lifesciences' operations related to active pharmaceutical ingredients and formulations.

Corporate Governance Implications

These changes in key management personnel have been formally disclosed to the company's Board of Directors and relevant regulatory bodies, in compliance with corporate governance norms. The company has emphasized that these transfers are in accordance with the terms of the business transfer agreement.

As Nectar Lifesciences navigates this organizational change, stakeholders will be observing how the company adapts its operations and maintains its market position in the pharmaceutical sector. The retention of Dr. Senthilkumar as a Non-Executive Director suggests a strategy to maintain continuity and leverage existing expertise during this transition period.

Nectar Lifesciences Limited has successfully completed the slump sale of its active pharmaceutical ingredients (API) and formulations business to Cephi Lifesciences Private Limited. The transaction, which also included an asset sale to the same purchaser, was finalized on November 10, 2025, following the execution of business transfer and asset purchase agreements on July 07, 2025.

Transaction Details

The completion of this significant corporate action includes all deliverables as outlined in the respective agreements. This move represents a substantial shift in Nectar Lifesciences' business structure and operations.

Management Changes

As part of this transition, several key management changes have taken place:

All four individuals have ceased their employment with Nectar Lifesciences and have been transferred to Cephi Lifesciences Private Limited, effective November 10, 2025, in accordance with the terms of the business transfer agreement.

Continued Involvement

It's worth noting that Dr. Surulichamy Senthilkumar, while resigning from his position as Whole-time Director, will continue to serve as a Non-Executive Director of Nectar Lifesciences Limited. However, this role will be without remuneration or sitting fees until further notice.

Implications

This transaction marks a significant milestone for Nectar Lifesciences, potentially reshaping its business focus and operational structure. The transfer of key personnel to Cephi Lifesciences, along with the API and formulations business, suggests a strategic realignment for both companies involved in the deal.

As the pharmaceutical landscape continues to evolve, this move may have implications for Nectar Lifesciences' future direction and market positioning. Stakeholders will likely be watching closely to see how this transaction impacts the company's performance and strategy in the coming months.